Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 15 | 15 |
| 2005 | 0 | 15 | 15 |
| 2006 | 0 | 20 | 20 |
| 2007 | 0 | 26 | 26 |
| 2008 | 0 | 23 | 23 |
| 2009 | 0 | 23 | 23 |
| 2010 | 0 | 37 | 37 |
| 2011 | 12 | 27 | 39 |
| 2012 | 24 | 21 | 45 |
| 2013 | 15 | 17 | 32 |
| 2014 | 17 | 21 | 38 |
| 2015 | 9 | 8 | 17 |
| 2016 | 13 | 10 | 23 |
| 2017 | 8 | 16 | 24 |
| 2018 | 26 | 23 | 49 |
| 2019 | 33 | 22 | 55 |
| 2020 | 41 | 23 | 64 |
| 2021 | 33 | 27 | 60 |
| 2022 | 2 | 18 | 20 |
| 2023 | 1 | 20 | 21 |
| 2024 | 31 | 17 | 48 |
| 2025 | 25 | 9 | 34 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov; 26(6):967-979.
-
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials. J Thorac Oncol. 2025 Dec; 20(12):1778-1790.
-
A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease. Inflamm Bowel Dis. 2025 Aug 01; 31(8):2269-2285.
-
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.
-
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events. Am J Hematol. 2025 Oct; 100(10):1839-1850.
-
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025 Jul 26; 406(10501):358-375.
-
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1?
-
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. Clin Lung Cancer. 2025 Nov; 26(7):541-551.
-
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 Sep 02; 135(17).
-
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul; 21(16):2007-2016.
People
People who have written about this concept.
Explore
_
Similar Concepts
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.